Abstract Relaxin-3 (also known as INSL7) is a recently identified neuropeptide belonging to the insulin/relaxin superfamily. It has putative roles in the regulation of stress responses, food intake, and reproduction by activation of its cognate G-protein-coupled receptor RXFP3. It also binds and activates the relaxin family peptide receptors RXFP1 and RXFP4 in vitro. To obtain a europium-labeled relaxin-3 as tracer for studying the interaction of these receptors with various ligands, in the present work we propose a novel site-specific labeling strategy for the recombinant human relaxin-3 that has been previously prepared in our laboratory. First, the N-terminal 69His-tag of the single-chain relaxin-3 precursor was removed by Aeromonas aminopeptidase and all of the primary amines of the resultant peptide were reversibly blocked by citroconic anhydride. Second, the A-chain N-terminus of the blocked peptide was released by endoproteinase Asp-N cleavage that removed the linker peptide between the B-and A-chains. Third, an alkyne moiety was introduced to the newly released A-chain N-terminus by reaction with the highly active primary amine-specific N-hydroxysuccinimide ester. Fourth, after removal of the reversible blockage under mild acidic condition, europium-loaded DOTA with an azide moiety was introduced to the twochain relaxin-3 carrying the alkyne moiety through click chemistry. Using this site-specific labeling strategy, homogeneous monoeuropium-labeled human relaxin-3 could be obtained with good overall yield. In contrast, conventional random labeling resulted in a complex mixture that was poorly resolved because human relaxin-3 has four primary amine moieties that all react with the modification reagent. Both saturation and competition binding assays demonstrated that the DOTA/Eu 3? -labeled relaxin-3 retained high binding affinity for human RXFP3, RXFP4, and RXFP1 and was therefore a suitable non-radioactive and stable tracer to study the interaction of various natural or designed ligands with these receptors. Using this sitespecific labeling strategy, other functional probes, such as fluorescent dyes, biotin, or nanoparticles could also be introduced to the A-chain N-terminal of the recombinant human relaxin-3. Additionally, we improved the timeresolved fluorescence assay for the DOTA-bound europium ion which paves the way for the use of DOTA as a lanthanide chelator for protein and peptide labeling in future studies.
Introduction
Relaxin-3 (also known as INSL7) is a new member of the insulin/relaxin superfamily (Shabanpoor et al. 2009; Smith et al. 2011b; Tanaka 2010) . It was identified in 2002 by a search of the human genome based on the cysteine pattern of the B-chain of the insulin superfamily Burazin et al. 2002) . Relaxin-3 is predominantly expressed in the nucleus incertus of the brain Burazin et al. 2002; Ma et al. 2009; Silvertown et al. 2010; Tanaka et al. 2005) . Administration of exogenous relaxin-3 in rats (Banerjee et al. 2010; Hida et al. 2006; McGowan et al. 2005 McGowan et al. , 2006 McGowan et al. , 2007 McGowan et al. , 2008 Tanaka et al. 2005; Watanabe et al. 2011a ) and gene knockout experiments (Smith et al. 2009a (Smith et al. , b, 2011a Watanabe et al. 2011b) showed that the peptide is involved in the regulation of the stress response, food intake, reproduction, as well as arousal and exploratory behaviors. The biological function of relaxin-3 is mediated by its cognate receptor RXFP3 that is also primarily expressed in the brain (Liu et al. 2003b ). Relaxin-3 also binds and activates RXFP1 and RXFP4 in vitro, the cognate receptors of relaxin and INSL5, respectively (Hsu et al. 2002; Liu et al. 2003a Liu et al. , 2005 Sudo et al. 2003) . Since relaxin-3 is the agonist of three of four known relaxin-family peptide receptors (RXFP1-4), it is a good model for studying the interaction of these G-protein-coupled receptors with relaxin-family peptides. For the receptor-ligand interaction studies, a labeled tracer that can be easily and sensitively detected is needed. Conventionally, radionuclides, such as 125 I, are used to label proteins and peptides. However, the use of radionuclides has drawbacks, such as their short-half life, high cost, and safety concerns. In recent years, lanthanides such as Eu 3? , Tb 3? , and Sm 3? have been used for protein and peptide labeling due to their highly sensitive timeresolved fluorescence (TRF) and non-radioactive property (Selvin 2002) .
To obtain a europium-labeled relaxin-3 as nonradioactive and stable tracer for receptor-ligand interaction studies, in the present work we propose a novel site-specific labeling strategy for the recombinant human relaxin-3 that has been previously prepared in our laboratory (Luo et al. 2010) . Using this strategy, homogeneous DOTA/Eu 3? -labeled relaxin-3 retaining high receptor binding affinity could be obtained with good overall yield (typically 50-100 lg of labeled peptide from 1.0 mg of folded relaxin-3 precursor). In contrast, conventional random labeling approach resulted in a complex labeling mixture that was poorly resolved on rp-HPLC because human relaxin-3 has four active primary amine moieties (two N-terminus a-amines and two internal side-chain e-amines) that all react with the labeling reagent.
Materials and methods

Materials
The Agilent reverse-phase columns (analytical column: Zorbax 300SB-C18, 4.6 mm 9 250 mm; semi-preparative column: Zorbax 300SB-C18, 9.4 mm 9 250 mm) were used in the experiments. The peptide was eluted from the C18 reverse-phase column by an acidic acetonitrile gradient composed of solvent A and solvent B. Solvent A was 0.1% aqueous TFA, and solvent B was acetonitrile containing 0.1% TFA. The elution gradient was listed as follows: 0 min, 10% solvent B; 3 min, 10% solvent B; 53 min, 60% solvent B; 55 min, 100% solvent B; 56 min, 100% solvent B, 60 min, 10% solvent B. The flow rate for analytical column was 0.5 ml/min and that for semi-preparative column was 1.0 ml/min. The eluted peptide was detected by UV absorbance at both 280 and 214 nm.
69His-tag removal by Aeromonas aminopeptidase
The recombinant single-chain human relaxin-3 precursor (69His-relaxin-3) was prepared according to our previous procedure (Luo et al. 2010 ). The refolded precursor was dissolved in the aminopeptidase digestion buffer (50 mM Tris-HCl, 1.0 M guanidine chloride, pH 8.0) at the final concentration of *5 mg/ml. Then Aeromonas aminopeptidase (Sigma-Aldrich, St. Louis, USA) stock solution was added (1 U enzyme vs. 2-3 mg peptide) to remove the N-terminus 69His-tag. The digestion was carried out at 30°C overnight. Thereafter, the digestion mixture was acidified by TFA and subjected to C18 rp-HPLC.
The eluted peptide fraction was manually collected, lyophilized, and subjected to mass spectrometry analysis.
Reversible primary amine blockage by citroconic anhydride
The above single-chain relaxin-3 without 69His-tag was suspended in the blocking buffer (100 mM sodium phosphate, pH 8.0) at a final concentration of *5 mg/ml (*730 lM). The freshly prepared citraconic anhydride (Sigma-Aldrich, St. Louis, USA) stock solution (in DMSO) was then added to a final concentration of 20 mM. The pH value of the reaction mixture was monitored and kept at 7-8 by adding 1.0 M NaOH solution. The blocking reaction was carried out at 4°C for 30 min. Thereafter, the excess amount of blocking reagent was removed by gel filtration (Sephadex G-25 column) that was pre-equilibrated by 10 mM Tris-HCl buffer (pH 8.0). The blocked single-chain relaxin-3 was eluted from the gel filtration column, manually collected, and lyophilized.
Endoproteinase Asp-N digestion
The above lyophilized blocked single-chain relaxin-3 (containing Tris-HCl salt) was dissolved by adding an appropriate amount of water (the final peptide concentration was *5 mg/ml). Endoproteinase Asp-N (Sigma-Aldrich, St. Louis, USA) solution was then added (mass ratio of peptide to enzyme 5,000:1) to remove the linker peptide between the B-and A-chains. The digestion was carried out at 30°C overnight. After digestion, the sample was applied to a gel filtration column (Sephadex G-25) that was pre-equilibrated with 10 mM sodium phosphate buffer (pH 8.0). The peptide was eluted from the column using 10 mM phosphate buffer (pH 8.0), manually collected, and lyophilized.
Alkyne-moiety introduction and deblocking
The above lyophilized blocked two-chain human relaxin-3 (containing phosphate salt) was dissolved by adding an appropriate amount of water to a final concentration of *2 mg/ml (*350 lM). Thereafter, the stock solution (in DMSO) of acetylene-PEG4-NHS ester (Click Chemistry Tools, Macon, USA) was added to the final concentration of 5.0 mM to irreversibly modify the newly released A-chain N-terminus. The modification reaction was carried out at 25°C for 3 h. Thereafter, 1.0 M Tris-HCl stock solution (pH 7.4) was added to a final concentration of 50 mM to react with the excess amount of the modification reagent. Subsequently, the mixture was 20-fold diluted into 10% aqueous acetic acid solution to remove the citroconic acid blockage. The deblocking reaction was carried out at 25°C for 36 h. Finally, the deblocking mixture was subjected to C18 rp-HPLC and was eluted by an acidic acetonitrile gradient. The eluted peptide fraction was manually collected, lyophilized, and analyzed by mass spectrometry.
Introduction of DOTA-bound europium ion through click chemistry
To form the DOTA/Eu 3? complex, EuCl 3 (Sigma-Aldrich, St. Louis, USA) solution (80 mM in water) was mixed with an equal volume of azido-mono-amide-DOTA (Macrocyclics, Dallas, USA) solution (40 mM in water). The pH of the mixture was then adjusted to *7 by adding NaOH solution (checked by pH paper). The mixture was kept at room temperature for 10-20 min to allow the complex to form and could then be stored at -20°C for several months. To form the CuBr/TBTA complex, one volume of fresh CuBr (Sigma-Aldrich, St. Louis, USA) solution (100 mM in DMSO/t-BuOH solvent, vol/vol 3:1, containing 10 mM ascorbate) was mixed with two volumes of TBTA (Sigma-Aldrich, St. Louis, USA) solution (100 mM in DMSO/t-BuOH solvent, vol/vol 3:1). The CuBr/TBTA complex should be freshly prepared. The above lyophilized two-chain relaxin-3 carrying an alkyne moiety at the A-chain N-terminus was dissolved in DMSO/t-BuOH solvent (vol/vol 3:1) at a final concentration of 5-10 mg/ml. Thereafter, the above DOTA/Eu 3? complex (molar ratio of peptide to DOTA at *1:5) and CuBr/TBTA complex (molar ratio of peptide to CuBr at *1:10) was added to initiate the click chemistry reaction that was carried out at 20°C overnight. Thereafter, the reaction solution was diluted by water, acidified to pH 3.0, and applied to C18 rp-HPLC. The DOTA/Eu 3? -labeled peptide was eluted from the C18 reverse-phase column by an acidic acetonitrile gradient, manually collect, lyophilized, and analyzed by mass spectrometry.
Time-resolved fluorescence measurement for the DOTA-bound europium ion An appropriate amount of the DOTA/Eu 3? -labeled relaxin-3 sample was added into a 96-well clear plate, then 50 ll of 2.0 M aqueous HCl solution was added to dissociate the europium ion from the DOTA chelator. The dissociation was carried out at 37°C overnight in a sealed humid chamber. Subsequently, *50 ll of neutralizing solution (2.0 M glycine, 2.0 M NaOH) was added and mixed to adjust the pH value to 3-4. The accurate volume of the neutralizing solution should be carefully checked according to the pH value of the neutralized solution. Then, 150 ll of enhancer solution (PerkinElmer, Waltham, MA, USA) was immediately added and well mixed. After 2-3 h gentle shaking, the time-resolved fluorescence was measured on a Spectramax M5 plate reader (at Tongji University) or on a Victor 3 plate reader (at Florey Institute).
Saturation binding of the DOTA/Eu 3? -labeled relaxin-3 with relaxin family peptide receptors
The saturation binding assays on human RXFP1 (at Florey Institute) were carried out as described previously (Shabanpoor et al. 2008 ) while those on human RXFP3 and human RXFP4 (at Tongji University) were carried out according to a slightly modified procedure. The genes of human RXFP3 and human RXFP4 were PCR amplified using human genomic DNA as template since they do not contain introns. The amplified DNA fragments were then cloned into the pcDNA6 vector and sequenced. Thereafter, the expression constructs were transfected into HEK293T cells using the transfection reagent Lipofectmine 2000 (Invitrogen, Carlsbad, CA, USA) according to the users' manual. On the second day, the transfected cells were trypsinized and seeded onto 96-well plates. After the cells grew to near confluency (24-48 h), the medium was removed and the saturation binding solution (200 ll/well) containing different concentrations of the DOTA/Eu 3? -relaxin-3 was added. The binding solution was serum-free DMEM/F-12 medium plus 1% BSA. After incubation at 20-22°C for 2 h, the assay solution was removed and the cells were washed with cold wash solution (serum-free DMEM/F-12 medium, 200 ll/well) twice. Thereafter, 2 M HCl solution (50 ll/well) was added and the plate was incubated at 37°C overnight in a sealed humid chamber to dissociate Eu 3? from DOTA. The TRF was measured according to the aforementioned improved procedure. The non-specific binding value was obtained by competition with 1.0 lM of mature human relaxin-3. The specific binding data were fitted with the one-site binding model using the software SigmaPlot 10.0.
Competition receptor binding using DOTA/Eu 3? -labeled relaxin-3 as tracer
The competition binding assays on human RXFP1 (at Florey Institute) were carried out as described previously (Shabanpoor et al. 2008 ) while those on human RXFP3 and human RXFP4 (at Tongji University) were carried out according to a slightly modified procedure. The HEK293T cells transiently expressing RXFP3 or RXFP4 were prepared according to the aforementioned description. For the competitive binding assay, the competition binding solution (200 ll/well) containing constant concentration of DOTA/Eu 3? -relaxin-3 and varied concentrations of competitor was added. The binding solution was serum-free DMEM/F12 medium with 1% BSA. After incubation at 20-22°C for 2 h, the competition binding solution was removed and the cells were washed with cold wash solution (serum-free DMEM/F-12 medium, 200 ll/well) twice. Thereafter, TRF was measured according to the improved procedure. The non-specific binding value was obtained by competition with 1.0 lM of competitor. The specific competition binding data were fitted by sigmoidal curves using the software SigmaPlot 10.0.
Results
Rationale of a site-specific labeling strategy for the recombinant human relaxin-3
In the previous work (Luo et al. 2010) we designed and recombinantly expressed a single-chain relaxin-3 precursor (Fig. 1a) that can be enzymatically converted to mature two-chain human relaxin-3 (Fig. 1b) . To obtain europiumlabeled relxin-3 as tracer for ligand-receptor interaction studies, we first tried random labeling using the mature recombinant human relaxin-3 and the commercially available labeling reagent DELFIA Eu-DTPA ITC chelate. Unfortunately, random labeling resulted in a very complex labeling mixture that was poorly resolved on rp-HPLC (data not shown) because human relaxin-3 has four primary amine moieties that all react with the labeling reagent. This phenomenon has also been observed in the random labeling of human INSL3 that has three primary amine moieties (Shabanpoor et al. 2008) . Therefore, we proposed a novel site-specific labeling strategy for the recombinant human relaxin-3 (Fig. 1c) . First, the N-terminal 69His-tag of the refolded 69His-relaxin-3 precursor was removed by Aeromonas aminopeptidase that can remove residues one by one from the N-terminus, but cannot cleave Glu or Asp residue. The resultant single-chain relaxin-3 without the 69His-tag was designated as I-1. Second, the N-terminal a-amine and two internal e-amines of I-1 were reversibly blocked by citroconic moieties, and the resultant blocked peptide was designated as I-2. The citroconic modification is stable under neutral and alkaline condition, but can be readily removed under mild acidic condition (pH 3-4). Third, I-2 was treated by endoproteinase Asp-N to remove the linker peptide between the B-and A-chains, and releasing a new A-chain N-terminus. The blocked twochain relaxin-3 was designated as I-3. Fourth, the newly released A-chain N-terminus in I-3 was irreversibly modified by acetylene-PEG4-NHS ester that carries a terminal alkyne moiety and a highly active primary amine-specific NHS ester moiety. The resultant intermediate carrying an alkyne moiety was designated as I-4. Fifth, the citraconic blockage in I-4 was removed under acidic condition, and the resultant deblocked intermediate carrying an alkyne-moiety was designated as I-5. Sixth, various functional moieties, such as metal ion-chelators, biotin, fluorescent dyes, or nanoparticles, with an attached azido moiety could be introduced to I-5 through Cu ? -catalyzed cycloaddition between the alkyne moiety and the azido moiety. In the present work, europium ion bound with the extremely tight lanthanide chelator DOTA was introduced to the recombinant human relaxin-3. Due to the sensitive TRF of the europium ion, the DOTA/Eu 3? -labeled relaxin-3 was expected to be a suitable non-radioactive tracer for studying the interaction of relaxin-family peptide receptors with their various natural or designed ligands.
69His-tag removal, reversible blocking, and endoproteinase Asp-N digestion
The recombinant single-chain 69His-relaxin-3 precursor was prepared according to our previous procedure (Luo et al. 2010) . Thereafter, the refolded precursor was subjected to Aeromonas aminopeptidase digestion in order to remove the N-terminal 69His-tag. As analyzed by C18 rp-HPLC (Fig. 2) , a major peak (indicated by a star) appeared after digestion. Its measured molecular mass was 7,691.0, that was consistent with the expected value (7,691.6) of the single-chain relaxin-3 without 69His-tag (I-1 in Fig. 1c) . Next, the three primary amines of the single-chain relaxin-3 (I-1), including one N-terminus a-amine and two internal e-amines, were reversibly blocked by citroconic moieties (II-2 in Fig. 1c) . To prevent non-specific modification, the reaction was carried out at low temperature. The excess amount of the modification reagent was removed by gel filtration, and the peptide fraction eluted by neutral Tris-HCl solution was then lyophilized, re-dissolved, and digested by endoproteinase Asp-N to remove the linker peptide between the B-and A-chains (I-3 in Fig. 1c) . The enzyme Asp-N showed higher activity in Tris solution than in phosphate solution, so Tris-HCl solution was used for digestion. After digestion, the peptide was exchanged into phosphate buffer that was compatible with the next step amine-specific modification. Introduction of an alkyne-moiety to the A-chain N-terminus of the recombinant relaxin-3 After endoproteinase Asp-N digestion, the newly released A-chain N-terminus of the blocked two-chain relaxin-3 was irreversibly modified by primary amine-specific modification reagent acetylene-PEG4-NHS ester. Through this modification, a terminal alkyne moiety was irreversibly introduced (I-4 in Fig. 1c) . Thereafter, the acid labile citroconic blockage was removed in acid solution (I-5 in Fig. 1 ). As analyzed by C18 rp-HPLC (Fig. 3) , a major peak (indicated by a star) appeared on rp-HPLC after deblocking. Its measured molecular mass (6,029.0) was consistent with the expected value (6,028.0) of the two-chain relaxin-3 carrying a single alkyne moiety (I-5 in Fig. 1c ). The alkyne moiety was a uniquely active group in this intermediate that could react with an azido moiety through click chemistry that was first introduced by Barry Sharpless in 2001 (Kolb et al. 2001) and is now widely used for labeling of biomolecules due to its bioorthogonal properties.
Introduction of DOTA-bound europium ion to human relaxin-3 through click chemistry
The reagent azido-mono-amide-DOTA was preloaded with Eu 3? through incubation with EuCl 3 solution. This prevented chelation of Cu(I) ion which is used in the click chemistry reaction. After the Cu ? -catalyzed cycloaddition, a major peak (indicated by a star) appeared on C18 rp-HPLC that was eluted by the acidic acetonitrile gradient (Fig. 4a) . This major peak was manually collected, lyophilized, and analyzed by mass spectrometry. As shown in Fig. 4b , its measured molecular mass (6,664.0) was consistent with the theoretical value (6,666.5) of the monoeuropium labeled relaxin-3, suggesting that the europium ion did not dissociate from DOTA even when eluted by the acidic acetonitrile gradient (0.1% TFA). The yield was typically 50-100 lg of DOTA/Eu 3? -labeled peptide from 1.0 mg of the folded relaxin-3 precursor.
Optimizing the time-resolved fluorescence measurement of the DOTA-bound europium ion
The tight binding between Eu 3? and DOTA simplified the purification of the labeled relaxin-3 since the labeled peptide could be eluted by the conventionally used acidic solvent from rp-HPLC without loss of europium ion. However, the tight binding made the time-resolved fluorescence (TRF) measurement difficult because dissociation of europium from DOTA is a prerequisite for this measurement. According to a previous report (De Silva et al. 2010) , we used 2.0 M aqueous HCl to dissociate the europium ion from DOTA before TRF measurement. However, we found that the reported subsequent neutralization procedure (De Silva et al. 2010 ) by 2.0 M NaOH solution was problematic during our work. The TRF measurement was very sensitive to pH but the enhancer solution is a poor buffer, so a little more or less of the neutralizing NaOH solution significantly changed the pH of Fig. 2 HPLC analysis of the human relaxin-3 precursor after Aeromonas aminopeptidase digestion. After digestion, 2 ll of the digestion mixture (*10 lg peptide) was removed, acidified by TFA, and applied to analytical C18 rp-HPLC that was eluted by an acidic acetonitrile gradient. The eluted peptide peak (indicated by a star) was manually collected, lyophilized, and subjected to mass spectrometry analysis. The expected mass value was listed in the parenthesis Fig. 3 HPLC analysis of the two-chain relaxin-3 carrying an alkynemoiety at the A-chain N-terminus. The single-chain relaxin-3 (without 69His-tag) was sequentially subjected to reversible blocking, Asp-N digestion, acetylene-PEG4-NHS ester modification, and deblocking. After the sequential treatment, 100 ll (*10 lg peptide) of the deblocking mixture was applied to analytical C18 rp-HPLC that was eluted by an acidic acetonitrile gradient. The eluted peptide peak (indicated by a star) was manually collected, lyophilized, and subjected to mass spectrometry analysis. The expected mass value was listed in the parenthesis the neutralized solution. Therefore, the TRF measurement could not be repeated when we used the manual pipettor to add the dissociation and neutralization solutions (data not shown). So we decided to use a reagent with high buffering capacity at pH 3-4 to stabilize the pH of the neutralized solution. As shown in Fig. 5 , when a high concentration of glycine was included in the neutralizing solution (2.0 M NaOH, 2.0 M glycine), the TRF assay showed good reproducibility. The measured TRF values of the europium standard whether subjected to acidification/neutralization (filled circles) or not (open circles) were similar when the plateau was reached, but a longer time (2-3 h) was needed to reach the plateau for the acidification/neutralizationtreated sample. For the DOTA/Eu 3? -labeled relaxin-3, the TRF could be detected only after the acidification/neutralization treatment (filled squares). According to the measured Eu quantity and the relaxin-3 peptide quantity estimated from the HPLC peak area, the molar ratio of europium ion to relaxin-3 peptide was about 1:1 which was consistent with the result of mass spectrometry analysis.
Saturation binding of the DOTA/Eu 3? -labeled relaxin-3 with relaxin family peptide receptors To test whether the DOTA/Eu 3? -labeled relaxin-3 retained receptor-binding activity, we first carried out saturation binding assays using the transiently expressed receptors on HEK293T cells as the receptor source. As shown in Fig. 6a , the binding curve of the labeled relaxin-3 on human RXFP3, the cognate receptor of relaxin-3, was typically hyperbolic. The measured data could be well fitted by the hyperbolic ligand binding function Y = B max X/(K d ? X). The calculated K d for RXFP3 was 1.9 ± 0.2 nM, suggesting the DOTA/Eu 3?
-labeled peptide could bind RXFP3 with high affinity despite the presence of the large DOTA/Eu 3? moiety. As shown in Fig. 6b , the labeled relaxin-3 could also bind to human RXFP4, the cognate receptor of INSL5, in a hyperbolic manner. The calculated K d for RXFP4 was 5.4 ± 0.8 nM. As shown in Fig. 6c , the labeled relaxin-3 could also bind to human RXFP1, the cognate receptor of relaxin, in a hyperbolic manner. The calculated K d for RXFP1 was 15.9 ± 2.3 nM. analyses of the human relaxin-3 labeled by the DOTA-bound europium ion. The two-chain relaxin-3 carrying an alkyne-moiety was reacted with the europiumloaded azido-mono-amide-DOTA at 20°C overnight. After cycloaddition, 2 ll of the reaction mixture (*10 lg peptide) was applied to analytical C18 rp-HPLC that was eluted by an acidic acetonitrile gradient. The eluted peptide peak (indicated by a star) was manually collected, lyophilized, and subjected to mass spectrometry analysis. The expected molecular mass was listed in the parenthesis -labeled relaxin-3 using our improved neutralization procedure. Open circle, 0.1 pmol of europium standard was directly mixed with 200 ll of enhancer solution. Filled circle, 0.1 pmol of europium standard was subjected to sequential acidification and neutralization before addition of 150 ll enhancer solution. Open square, europiumlabeled relaxin-3 (*0.1 pmol estimated from HPLC peak area) was directly mixed with 200 ll of enhancer solution. Filled square, europium-labeled relaxin-3 (*0.1 pmol estimated from HPLC peak area) was subjected to sequential acidification and neutralization before addition of 150 ll enhancer solution. After being mixed, the TRF was measured on a Spectramax M5 plate reader at different times. The data were shown as mean ± SD, n = 3 Site-specific DOTA/europium-labeling of recombinant human relaxin-3 989
The aforementioned saturation binding assays showed that the DOTA/Eu 3?
-labeled relaxin-3 retained binding affinity for RXFP3, RXFP4, and RXFP1. Therefore, we used the labeled peptide as tracer in competition receptor-binding assays to study the interaction of these receptors with their ligands. As shown in Fig. 7 , the competitive binding data on human RXFP3, RXFP4, and RXFP1 were all typical sigmoidal curves when DOTA/Eu -labeled relaxin-3 tracer was used in the competition assays. The calculated pIC50 values for human relaxin-2 (H2 relaxin) and human relaxin-3 (H3 relaxin) binding on human RXFP1 were 8.83 ± 0.17 and 7.93 ± 0.20, respectively, indicating that relaxin-2 had approximately tenfold higher RXFP1-binding affinity than relaxin-3.
Discussion
In the present work, we developed an efficient approach for site-specific labeling of recombinant relaxin-3 by which various functional probes could be site-specifically introduced to the A-chain N-terminus of the recombinant human relaxin-3. The labeling approach is based on three major sequential steps: (i), reversible primary-amine blockage of a designed precursor; (ii), release of a new N-terminus through enzymatic removal of the designed pro-fragment; and (iii), irreversible modification of the newly released N-terminus by a functional probe or a suitable adaptor and subsequent removal of the reversible blockage. This approach could also be used for site-specific labeling of other recombinant peptides and proteins after slight modification. To introduce Eu 3? to the newly released A-chain N-terminus of human relaxin-3, we tried several methods. First, we used DTPA dianhydrate that is very active to primary amines. Unfortunately, the DTPA-modified relaxin-3 always had a molecular mass increase of 53 although we tried various modification conditions. The unexpected molecular mass increase was likely caused by modification of the DTPA moiety since the modified peptide lost Eu 3? -binding ability. This phenomenon was also observed in europium-labeling of the chemically synthesized INSL3 (Shabanpoor et al. 2008) . Thereafter, we used Eu 3? -preloaded SCN-Bn-DTPA to modify the newly released A-chain N-terminus. However, the modification efficiency was quite low although the modified peptide had the correct molecular mass. This was The data were expressed as mean ± SD (n = 3). The measured data were fitted by a hyperbolic ligand-receptor binding function Y = B max X/(K d ? X) using the software SigmaPlot 10.0. The linear Scatchard plots were shown in the inner panels. The non-specific binding was *20% of total binding for RXFP3, *30% for RXFP4, and *50% for RXFP1 probably due to the low reactivity of the SCN-moiety to primary amines. Finally, we tried a two-step procedure: introduction of an alkyne moiety through reaction with N-hydroxysuccinimide ester and subsequent introduction of DOTA-bound Eu 3? through click chemistry. This two-step procedure worked well and DOTA/Eu 3? -labeled relaxin-3 was obtained in good overall yield. The two-step labeling procedure also introduced a long hydrophilic arm between the peptide and the DOTA/Eu 3? probe. We expected that the long hydrophilic arm would be helpful for the activity of the labeled peptide due to the elimination of steric hindrance. Although a large DOTA/Eu 3? -moiety was introduced, the labeled relaxin-3 retained most of the binding affinity for RXFP3, RXFP4, and RXFP1, its measured K d values being only slightly lower than those of 125 I-labeled relaxin-3 (Liu et al. 2003a, b; Sudo et al. 2003) . The positioning of the DOTA/Eu 3? -moiety at the end of the A-chain is therefore appropriate for retaining high affinity for all the receptors and is consistent with the NMR solution structure of relaxin-3 (Rosengren et al. 2006 ) which shows that the N-terminus of the A-chain is on the opposite side of the peptide from the receptor interacting residues in the B-chain. Considering the superior stability of the DOTA/Eu 3? -labeled relaxin-3 to the 125 I-labeled peptide, the DOTA/Eu 3? -labeled relaxin-3 tracer was a good choice in the ligand-receptor interaction assays. As shown in Fig. 7 , the DOTA/Eu 3? -labeled relaxin-3 could monitor the ligand binding with three receptors (RXFP3, RXFP4, and RXFP1) and could discriminate the binding affinities of different ligands with one receptor.
For lanthanide labeling, a metal ion chelator is needed to be covalently attached to the target protein/peptide. In general, DTPA or DTTA, that have moderate binding affinity with lanthanides, are used since the bound lanthanide needs to be dissociated in the subsequent TRF measurement. Therefore, tight lanthanide chelators, such as DOTA, are rarely used for lanthanide-labeling and subsequent TRF assay. Recently, a procedure for TRF measurement of the DOTA-bound europium was reported (De Silva et al. 2010) . However, we found that the reported neutralizing procedure showed poor reproducibility due to lack of buffering capacity. So, we further improved the TRF measurement procedure for DOTA-bound europium and setup a robust assay system that showed good reproducibility. Since the DOTA/Eu 3? -labeled peptide could be eluted from rp-HPLC by the conventionally used acidic solvents (containing *0.1% of TFA) without europium loss, DOTA/Eu 3? -labeling had advantage over the conventionally used DTPA/Eu 3? -and DTTA/Eu 3? -labeling that had to be eluted by neutral solvents. Our successful TRF measurement of the DOTA-bound europium now allows DOTA/lanthanide-labeling to be widely used for protein/peptide labeling in future.
Acknowledgments This work was supported by the National Natural Science Foundation of China (30970609) labeled relaxin-3 as tracer. The measured data were shown as mean ± SD (n = 3), and fitted by the software SigmaPlot 10.0 Site-specific DOTA/europium-labeling of recombinant human relaxin-3 991 at the FNI were supported by the Victorian Government's Operational Infrastructure Support Program.
